Eiger BioPharmaceuticals, Inc. Quarterly Costs and Expenses in USD from Q1 2020 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
Eiger BioPharmaceuticals, Inc. quarterly/annual Costs and Expenses history and growth rate from Q1 2020 to Q4 2023.
  • Eiger BioPharmaceuticals, Inc. Costs and Expenses for the quarter ending December 31, 2023 was $16.4M, a 39.6% decline year-over-year.
  • Eiger BioPharmaceuticals, Inc. Costs and Expenses for the twelve months ending December 31, 2023 was $87.6M, a 17.6% decline year-over-year.
  • Eiger BioPharmaceuticals, Inc. annual Costs and Expenses for 2023 was $87.6M, a 17.6% decline from 2022.
  • Eiger BioPharmaceuticals, Inc. annual Costs and Expenses for 2022 was $106M, a 19.2% increase from 2021.
  • Eiger BioPharmaceuticals, Inc. annual Costs and Expenses for 2021 was $89.1M, a 43.3% increase from 2020.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2023 $87.6M $16.4M -$10.8M -39.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-04-08
Q3 2023 $98.3M $20.1M -$10.3M -33.7% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $109M $24.6M +$453K +1.87% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $108M $26.4M +$1.89M +7.71% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-11
Q4 2022 $106M $27.2M +$2.89M +11.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-08
Q3 2022 $103M $30.4M +$5.5M +22.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $97.8M $24.2M +$3.71M +18.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $94.1M $24.5M +$5.03M +25.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $89.1M $24.3M +$6.31M +35.1% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-17
Q3 2021 $82.8M $24.9M +$10.1M +67.8% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $72.7M $20.5M +$5.83M +39.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $66.9M $19.5M +$4.74M +32.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $62.1M $18M Oct 1, 2020 Dec 31, 2020 10-K 2023-03-17
Q3 2020 $14.8M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $14.6M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $14.7M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
* An asterisk sign (*) next to the value indicates that the value is likely invalid.